ATE238058T1 - Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel - Google Patents

Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel

Info

Publication number
ATE238058T1
ATE238058T1 AT96936018T AT96936018T ATE238058T1 AT E238058 T1 ATE238058 T1 AT E238058T1 AT 96936018 T AT96936018 T AT 96936018T AT 96936018 T AT96936018 T AT 96936018T AT E238058 T1 ATE238058 T1 AT E238058T1
Authority
AT
Austria
Prior art keywords
benzenesulfonamides
inflammatory agents
veterinary use
substituted pyrazolyl
pyrazolyl
Prior art date
Application number
AT96936018T
Other languages
German (de)
English (en)
Inventor
Peter C Isakson
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24138015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE238058(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE238058T1 publication Critical patent/ATE238058T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96936018T 1995-09-29 1996-09-27 Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel ATE238058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,318 US5756529A (en) 1995-09-29 1995-09-29 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
PCT/US1996/015538 WO1997011704A1 (en) 1995-09-29 1996-09-27 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents

Publications (1)

Publication Number Publication Date
ATE238058T1 true ATE238058T1 (de) 2003-05-15

Family

ID=24138015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936018T ATE238058T1 (de) 1995-09-29 1996-09-27 Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel

Country Status (21)

Country Link
US (1) US5756529A (cs)
EP (1) EP0854723B1 (cs)
JP (1) JPH11514991A (cs)
KR (1) KR100498730B1 (cs)
CN (1) CN1202828A (cs)
AT (1) ATE238058T1 (cs)
AU (1) AU718300B2 (cs)
BR (1) BR9610974A (cs)
CA (1) CA2233620C (cs)
CZ (1) CZ297183B6 (cs)
DE (1) DE69627683T2 (cs)
DK (1) DK0854723T3 (cs)
ES (1) ES2197954T3 (cs)
IL (1) IL123635A (cs)
NO (1) NO321157B1 (cs)
NZ (1) NZ320919A (cs)
PL (1) PL191934B1 (cs)
PT (1) PT854723E (cs)
RO (1) RO120408B1 (cs)
RU (1) RU2253456C2 (cs)
WO (1) WO1997011704A1 (cs)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
AU5886296A (en) * 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
JP2002538189A (ja) * 1999-03-10 2002-11-12 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターの投与方法と組成物
US6376519B1 (en) 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
CA2392931A1 (en) 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
EP1104758B1 (en) * 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
DK1104759T3 (da) * 1999-12-03 2004-01-26 Pfizer Prod Inc Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
ES2236007T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
YU57801A (sh) * 1999-12-08 2005-07-19 Pharmacia Corporation Polimorfni kristalni oblici celecoxib-a
MY127898A (en) * 1999-12-22 2006-12-29 Pharmacia Corp Dual-release compositions of a cyclooxygenase-2 inhibitor
EP1274424A4 (en) * 2000-04-12 2003-09-17 Smithkline Beecham Corp CONNECTIONS AND PROCEDURE
US20020107250A1 (en) * 2000-04-18 2002-08-08 Madhusudan Hariharan Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor
WO2001081333A2 (en) * 2000-04-25 2001-11-01 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE298749T1 (de) 2001-07-05 2005-07-15 Pfizer Prod Inc Heterocyclo-alkylsulfonyl pyrazole als entzündungshemmende/analgetische mittel
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1444207A2 (en) 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
CA2460939C (en) 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
WO2003037335A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
JP2005515171A (ja) 2001-11-02 2005-05-26 ファイザー・プロダクツ・インク ５−ヘテロ原子含有ピラゾールの効率的な合成法
JP2005528384A (ja) * 2002-04-08 2005-09-22 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 増殖性細胞においてアポトーシスを誘導するための化合物および方法
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
PL1608407T3 (pl) * 2003-03-20 2006-12-29 Pharmacia Corp Dyspergowana kompozycja środka przeciw-zapalnego
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US7659426B2 (en) * 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
RU2429853C2 (ru) * 2007-02-01 2011-09-27 Дзе Иамс Компани Способ уменьшения воспаления и окислительного стресса у млекопитающих
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
RU2406505C2 (ru) * 2007-06-29 2010-12-20 Федеральное государственное образовательное учреждение высшего профессионального образования "САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ АКАДЕМИЯ ВЕТЕРИНАРНОЙ МЕДИЦИНЫ" (ФГОУ ВПО СПГАВМ) Способ лечения воспалительного заболевания пясти и плюсны у собак
AU2011238616B2 (en) 2010-03-30 2016-08-04 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
BR112013019893A2 (pt) * 2011-02-03 2016-10-11 Lupin Ltd derivados de pirrol usados como moduladores de alfa7 nachr
CN103242233B (zh) * 2012-02-08 2014-07-30 北京博爱汇康医药科技有限责任公司 制备塞来昔布的新方法
US8859781B2 (en) * 2012-07-12 2014-10-14 Euclises Pharmaceuticals, Inc. No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents
CN110423221A (zh) 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
US9533970B2 (en) 2013-03-15 2017-01-03 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
PT3261639T (pt) 2015-02-27 2022-11-25 Verseon Int Corporation Compostos de pirazol substituídos como inibidores de serina protéase
CN107686465B (zh) * 2017-09-02 2020-10-27 东北农业大学 地拉考昔的制备方法
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
PT731795E (pt) * 1993-11-30 2000-05-31 Searle & Co Pirazolilbenzenossulfonamidas para o tratamento de inflamacoes

Also Published As

Publication number Publication date
EP0854723B1 (en) 2003-04-23
CA2233620A1 (en) 1997-04-03
IL123635A0 (en) 1998-10-30
AU7376896A (en) 1997-04-17
CZ297183B6 (cs) 2006-09-13
KR100498730B1 (ko) 2005-09-09
PT854723E (pt) 2003-08-29
PL191934B1 (pl) 2006-07-31
NO981392D0 (no) 1998-03-27
NZ320919A (en) 1999-10-28
AU718300B2 (en) 2000-04-13
DE69627683D1 (de) 2003-05-28
WO1997011704A1 (en) 1997-04-03
BR9610974A (pt) 1999-07-13
CZ89798A3 (cs) 1999-04-14
US5756529A (en) 1998-05-26
DE69627683T2 (de) 2003-12-18
CA2233620C (en) 2011-11-22
PL325952A1 (en) 1998-08-17
EP0854723A1 (en) 1998-07-29
CN1202828A (zh) 1998-12-23
DK0854723T3 (da) 2003-08-11
NO321157B1 (no) 2006-03-27
RU2253456C2 (ru) 2005-06-10
KR19990063874A (ko) 1999-07-26
RO120408B1 (ro) 2006-01-30
ES2197954T3 (es) 2004-01-16
IL123635A (en) 2003-06-24
JPH11514991A (ja) 1999-12-21
NO981392L (no) 1998-05-25

Similar Documents

Publication Publication Date Title
ATE238058T1 (de) Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel
PT946507E (pt) Compostos de pirrolilo substituidos para o tratamento da inflamacao
ATE301457T1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
DK0880350T3 (da) Behandling af dissemineret sklerose
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
ATE254447T1 (de) Verfahren zur phototherapeutischen behandlung von proliferativen hauterkrankungen
MY119711A (en) Method of inhibiting photoaging of skin
FR2810539B1 (fr) Procede et dispositif de traitement,notamment de maquillage, de coloration ou de soin cosmetique,de parties ou de la totalite du corps humain ou animal
YU58394A (en) Use of inhibitors of 5-alfa reductaze in the production of medicament used for the treatment of androgen alopecia
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
ATE178201T1 (de) Alkoholisches feuchtigkeitsspendendes after shave lotion
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
NO20002649L (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
FR2751541B1 (fr) Composition dermo-cosmetique contenant un alcaloide du quinquina et methode de traitement cosmetique de l'alopecie
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
NO950925D0 (no) Preparat og fremgangsmåte for behandling av hårtap
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
PT1135154E (pt) Melhoria da foliculogenese
RU94024337A (ru) Антиметастатическое средство
ES2099613T3 (es) Empleo de hidroxinaftalinas en agentes colorantes.
DE59603099D1 (de) Transdermales therapeutisches system für silatranverbindungen
NO954115L (no) Anvendelse av ceruletid-dietylaminsalt ved behandling av psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854723

Country of ref document: EP